NCT07199959

Study on the Mechanism of Acquired Resistance of Entrectinib

A Multi-center Retrospective Study of the Mechanism of Acquired Resistance in First Line Treatment of ROS1fusion Positive NSCLC With Entrectinib

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 38 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

The goal of this observational study is to learn about the mechanism of acquired resistance in first line trearment of ROS1-positive NSCLC with entrectinib. The main question it aims to answer is: what is the acquired resistant mechanism of entrectinib as first line treatment setting in patients? Tissue or blood samples of participants who have already taken entrectinib as their regular medical care for NSCLC will send for Next gene sequencing for genomic profiles and bioinformatic analysis.

Conditions

• ROS1 Fusion Positive
• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
PROCEDURE	venipuncyure	venipuncture as clinical practical setting
DRUG	Entrectinib	600mg, oral, once daily

Timeline

• Start date: 2025-01-15
• Primary completion: 2026-06-30
• Completion: 2026-12-01
• First posted: 2025-09-30
• Last updated: 2025-09-30

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study